Revised Consolidated Financial Statements for Fiscal 2025

Following the jury verdict in the antitrust litigation concerning AMITIZA, a litigation provision was recorded in the FY2025 consolidated financial statements, which have been revised accordingly. Core performance, the FY2026 earnings forecast, management guidance and the dividend forecast remain unchanged.

Worth reading

—

Scored from 0 of 4 sections

Direction

Mixed performance

Direction inferred from the company’s description.

Scale

—

Displayed only when the document provides numerical figures.

Wording

Definitive

How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Items this document does not state (6)

Type of shareholders' meetingDate and timeMatters for resolutionShareholder ProposalDirector nomineePercentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The calculation of the impact on the consolidated financial statements has been completed following the jury verdict in the antitrust litigation concerning AMITIZA (lubiprostone) in the U.S. District Court for the District of Massachusetts.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.